John Aballi

All filings by John Aballi on record concern Exagen Inc., in the capacity of chief executive. Between 16 October 2022 and 12 March 2026, the trades on record add up to 14 filings.

In open-market terms, that means 3 purchases worth €365k on one side and 4 sales worth €460k on the other. The net balance comes to €95k on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 7 share grants. So far in 2026, the count stands at no purchases and 2 sales.

Half of the purchases are above €71k and half below. The 3 purchases reviewed show no overlap with other insiders buying the same stock within a month.

Most recently, on 16 March 2026, the filings show a share grant in Exagen Inc. The clock since the last published purchase (18 November 2024) now reads 699 days. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.